Market5-HT2C receptor
Company Profile

5-HT2C receptor

The 5-HT2C receptor is a subtype of the 5-HT2 receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Like all 5-HT2 receptors, it is a G protein-coupled receptor (GPCR) that is coupled to Gq/G11 and mediates excitatory neurotransmission. HTR2C denotes the human gene encoding for the receptor, that in humans is located on the X chromosome. As males have one copy of the gene and females have one of the two copies of the gene repressed, polymorphisms at this receptor can affect the two sexes to differing extent.

Structure
At the cell surface the receptor exists as a homodimer. The crystal structure has been known since 2018. == Distribution ==
Distribution
5-HT2C receptors are located mainly in the choroid plexus, and in rats is also found in many other brain regions in high concentrations, including parts of the hippocampus, anterior olfactory nucleus, substantia nigra, several brainstem nuclei, amygdala, subthalamic nucleus and lateral habenula. 5-HT2C receptors are also found on epithelial cells lining the ventricles. == Function ==
Function
The 5-HT2C receptor is one of the many binding sites for serotonin. Activation of this receptor by serotonin inhibits dopamine and norepinephrine release in certain areas of the brain. 5-HT2C receptors are claimed to significantly regulate mood, anxiety, feeding, and reproductive behavior. 5-HT2C receptors regulate dopamine release in the striatum, prefrontal cortex, nucleus accumbens, hippocampus, hypothalamus, and amygdala, among others. Research indicates that some suicide victims have an abnormally high number of 5-HT2C receptors in the prefrontal cortex. Agomelatine, which is a 5-HT2C and 5-HT2B antagonist as well as a MT1 and MT2 agonist, is an effective antidepressant. It has been found to act, through its 5-HT2C receptor antagonism, as a norepinephrine-dopamine disinhibitor because antagonism of 5-HT2C results in an increase of dopamine and norepinephrine activity in the frontal cortex. Conversely, many atypical antipsychotic and antidepressants act as 5-HT2C receptor antagonists, like Loxapine, an antipsychotic structurally related to Clozapine and its metabolite Amoxapine, which is an antidepressant in its own right, act as 5-HT2C receptor antagonist. Fluoxetine acts as a direct 5-HT2C antagonist in addition to inhibiting serotonin reuptake, however, the clinical significance of this action is variable. Several tetracyclic antidepressants, including mirtazapine and Mianserin, are potent 5-HT2C antagonists; this action may contribute to their efficacy. In addition to the evidence for a role of 5-HT2C receptor stimulation in depressive symptoms there also is evidence that activation of 5-HT2C receptors may have beneficial effects upon certain aspects of depression, one group of researchers found that direct stimulation of 5-HT2C receptors with a 5-HT2C agonist reduced cognitive deficits in mice with a TPH2 loss-of-function mutation. 5-HT2C receptors mediate the release and increase of extracellular dopamine in response to many drugs, including caffeine, nicotine, amphetamine, morphine, cocaine, and others. 5-HT2C antagonism increases dopamine release in response to reinforcing drugs, and many dopaminergic stimuli. Feeding, social interaction, and sexual activity all release dopamine subject to inhibition of 5-HT2C. Increased 5-HT2C expression reduces dopamine release in both the presence and absence of stimuli. Conditions that increase cytokine levels in the human body may have potential to raise 5-HT2C gene expression in the brain. This could possibly comprise a link between viral infections and associated depression. Cytokine therapy has been shown to increase 5-HT2C gene expression, resulting in increased activity of 5-HT2C receptors in the brain . == Endocrinology ==
Endocrinology
Serotonin is involved in basal and stress-induced regulation of hypothalamus and pituitary gland hormones such as prolactin, adrenocorticotropic hormone (ACTH), vasopressin and oxytocin, mainly via actions of receptor subtypes 5-HT2A and 5-HT2C. Therefore, the 5-HT2C receptor is a significant modulator of the hypothalamic–pituitary–adrenal axis (HPA axis). The HPA axis is the main controller of acute sympathetic stress responses related to fight-or-flight response. Prolonged activation and disturbances of the HPA axis contribute to depressive and anxiety symptoms seen in many psychopathological conditions. Stimulation of 5-HT2C receptors leads to increase of corticotropin releasing hormone (CRH) and vasopressin mRNA in the paraventricular nucleus and proopiomelanocortin in the anterior pituitary lobe. In rats, restraint stress (which can produce depressive symptoms if being chronic) induces secretion of prolactin, ACTH, vasopressin and oxytocin which is partially mediated via 5-HT2C receptor. Responses during such conditions as dehydration or haemorrhage causes the release of oxytocin via serotonergic response that is partly mediated by 5-HT2C. In addition, peripheral release of vasopressin involves serotonergic response which is partially mediated via 5-HT2C. Expression of the 5-HT2C receptor in the CNS is modulated by female sex hormones estradiol and progesterone. Combination of the hormones decrease the receptor concentration in the ventral hippocampus in rats and could thus affect mood. == Genetics ==
Genetics
Many human polymorphisms have been identified influencing the expression of 5-HT2C. Significant correlations are suggested, specifically in relation to psychiatric disorders such as depression, OCD, and anxiety-related conditions. Polymorphisms also correlate with susceptibility to a number of conditions including substance use disorders and obesity. There are indications that the alternative splicing of the 5-HT2C receptor is regulated by a snoRNA called SNORD115, the deletion of which is associated with Prader–Willi syndrome. As the human gene is located in the X chromosome, males have only one copy of the gene whereas women have two, meaning that mutations in the gene affect the phenotype of men even when the allele would be recessive in nature. As women have two copies of the gene, but only one allele is expressed in each cell, they are a mosaic for polymorphisms, meaning that one genetic variant may be prevalent in one tissue and another variant will be prevalent in a different tissue (as with all other x-linked genetic variations). ==Ligands==
Ligands
AgonistsA-372,159AL-38022AAporphines and noraporphines (e.g., MQ02-439, nornuciferine, asimilobine, 11-chloroasimilobine, 11-methoxyasimilobine, (S)-glaucine) • ATHX-105BexicaserinBMB-101BMB-105BMB-201CenthaquineCP-132,484CP-809,101CPD-1DLX-2270FenfluramineKB-128LisurideLorcaserinLY03020MesulergineMK-212NaphthylisopropylamineNorfenfluramineNU-1223ORG-12962ORG-37684OxaflozanePF-04479745PNU-22394PNU-181731PRX-00933Psychedelics • Lysergamides (e.g., LSD) • Phenethylamines (e.g., mescaline, 2C-B, DOI, DOM, MDA, 25I-NBOMe) • Phenylpiperazines (e.g., mCPP, TFMPP) • Tryptamines (e.g., DMT, psilocin, psilocybin, 5-MeO-DMT, bufotenin, CPI-CG-8) • Ro60-0175VabicaserinVR-1065WAY-629WAY-161,503WAY-163,909WAY-261240YM-348 AntagonistsAgomelatineCEPCClozapineCyclobenzaprineEltoprazineEtoperidoneFlibanserinFluoxetineFR260010MethysergideMianserinMirtazapineNefazodoneNorfluoxetineO-DesmethyltramadolOlanzapinePromethazinePuerarinRS-102,221SB-200,646SB-221,284SB-228,357SB-242,084SDZ SER-082TedatioxetineTramadolTrazodone Peripherally selective antagonistsBW-501C67SarpogrelateXylamidine Inverse agonistsAntidepressantsTricyclics (Amitriptyline and Nortriptyline most notably) • Tetracyclics (Mirtazapine, Mianserin, Amoxapine, etc.) • Antihistamines (Cyproheptadine, Hydroxyzine, Latrepirdine, etc.) • Antipsychotics • Typicals (Chlorpromazine, Fluphenazine, Loxapine, Thioridazine, etc.) • Atypicals (Clozapine, Olanzapine, Risperidone, Ziprasidone, etc.) • CinanserinDeramciclaneKetanserinLY-53,857MetergolineMethiothepinPizotifenRitanserinS-32212SB-206,553SB-228,357SB-242,084SB-243,213SB-247853Tenilapine Positive allosteric modulators Exogenous PAMs of the serotonin 5-HT2C receptor include: • CYD-1-79CTW-0415VA012 == Interactions ==
Interactions
The 5-HT2C receptor has been shown to interact with MPDZ. == RNA editing ==
RNA editing
5HT2CR pre-mRNA can be the subject of RNA editing. It is the only serotonin receptor as well as the only member of the large family of 7 transmembrane receptors (7TMRs) known to be edited. Different levels of editing result in a variety of effects on receptor function. Type The type of RNA editing that occurs in the pre-mRNA of the 5HT2CR is Adenosine to Inosine (A to I) editing. A to I RNA editing is catalyzed by a family of adenosine deaminases acting on RNA (ADARs) that specifically recognize adenosines within double-stranded regions of pre-mRNAs and deaminate them to inosine. Inosines are recognised as guanosine by the cells translational machinery. There are three members of the ADAR family ADARs 1–3 with ADAR1 and ADAR2 being the only enzymatically active members. ADAR3 is thought to have a regulatory role in the brain. ADAR1 and ADAR2 are widely expressed in tissues while ADAR3 is restricted to the brain. The double stranded regions of RNA are formed by base-pairing between residues in the close to region of the editing site with residues usually in a neighboring intron but can be an exonic sequence. The region that base pairs with the editing region is known as an Editing Complementary Sequence (ECS). ADARs bind interact directly with the dsRNA substrate via their double stranded RNA binding domains. If an editing site occurs within a coding sequence, it can result in a codon change. This can lead to translation of a protein isoform due to a change in its primary protein structure. Therefore, editing can also alter protein function. A to I editing occurs in a non coding RNA sequences such as introns, untranslated regions (UTRs), LINEs, SINEs ( especially Alu repeats) The function of A to I editing in these regions is thought to involve creation of splice sites and retention of RNAs in the nucleus amongst others. Location Editing occurs in 5 different closely located sites within exon 5, which corresponds to the second intracellular loop of the final protein. The sites are known as A, B, C′ (previously called E), C and D, and are predicted to occur within amino acid positions 156, 158 and 160. Several codon changes can occur due to A-to-I editing at these sites. Thirty-two different mRNA variants can occur leading to 24 different protein isoforms. • An Isoleucine to Valine (I/V) at amino acid position 157,161. • An Isoleucine to a Methionine(I/M) at amino acid position 157 • An Aspartate to a Serine (N/S)at 159 • An Aspartate to Asparagine(N/D) at 159 • An Asparagine to a Glycine(N/G) at 159. These codon changes which can occur due to A to I editing at these sites can lead to a maximum of 32 different mRNA variants leading to 24 different protein isoforms. The number of protein isoforms is less than 32 since some amino acids are encoded by more than one codon. Another editing site, site F has also been located in the exon complementary sequence (ECS) of intron 5. The ECS required for formation of double stranded RNA structure is found within intron 5. The initial demonstration of RNA editing in rat. The editing complementary sequence is known to be conserved across Mammalia. Regulation The 5-HT2c receptor is the only serotonin receptor edited despite its close sequence similarities to other family members. Mice knock out and other studies have been used to determine which ADAR enzyme are involved in editing. Editing at A and B sites has been demonstrated to be due to ADAR1 editing. Also since ADAR1 expression is increased in response to the presence of interferon α, it was also observed that editing at A and B sites was also increased because of this. The C site has been shown to be mainly edited by ADAR2 but in presence of upregulated expression of ADAR1, there was an increase in editing of this site and the enzymes presence can also result in limited editing in ADAR 2 knock out mice. In contrast, the 5-HT2CR-INI is constitutively internalized and accumulates in endosomes 78. Structure As mentioned editing results in several codon changes. The editing sites are found in the second intracellular domain of the protein which is also the receptors G protein coupling domain. Therefore, editing of these sites can affect the affinity of the receptor for G protein binding. Editing is also thought to influence splicing. Three different spliced isoforms of the receptor exist. Editing regulates the amount of 5HT2CR mRNA which leads to translation of the full length protein selection of alternative splice sites. t76,77. These splice sites are termed Gu1, Gu2, GU3. Only GU2 site splicing results in translation of the full length receptor while editing at GU1 is known to result in translation of a truncated protein. This is thought to be a regulatory mechanism to decrease the amount of unedited isoform INI to limit serotonin response when editing is inefficient. Most of the pre-mRNAs which are edited are spliced at the GU2 site. There have been several experimental investigations into the effects of alternative editing patterns of the 5HT2CR and these conditions with a wide variability in results especially those relating to schizophrenia. Some studies have noted that there is an increase in RNA editing at site A in depressed suicide victims. In rat models this increase is also observed and can be reversed with fluoxetine with some suggestion that E site editing maybe linked to major depression. == See also ==
tickerdossier.comtickerdossier.substack.com